Compound knowledge base
Fifteen Schedule I and adjacent compounds. Each carries PubMed-cited receptor binding data, metabolic pathways, drug interactions, toxicology, and FDA status. Queryable by target, potency, or class.
Fifteen Schedule I compounds, PubMed-cited. Twenty-nine PhD-trained AI expert agents, grounded in real literature and federal regulation. A DEA Schedule I application drafted in two weeks, not three months.
Built by Michael Crowe, founder of Southwest Mushrooms, author of The Mushroom Grower, principal architect of CriOS Nova and the Crowe Logic AI platform.
A working commercial stack built on top of CriOS Nova, Crowe Logic's chemoinformatics engine, and a 194-agent architecture specialized for psychedelic tryptamines, phenethylamines, ergolines, and related scaffolds.
Fifteen Schedule I and adjacent compounds. Each carries PubMed-cited receptor binding data, metabolic pathways, drug interactions, toxicology, and FDA status. Queryable by target, potency, or class.
Twenty-four Molecular Design specialists, three Psychedelic Specialists, and two Core orchestrators. Each one is an AI composite persona grounded in real literature. The reasoning is PhD-grade; the disclosure is honest.
Six Psilocybe species and six commercial P. cubensis strains with peer-reviewed alkaloid profiles. Match a target alkaloid profile to ranked cultivar and strain candidates with predicted dry-weight percentages.
No signup, no install. Everything below runs on real platform data. The compound browser reads the same records the CLI does. The cultivar matcher uses the same scoring algorithm. The agent reveal streams previously generated output from Dr. Nakamura and Dr. Mullen.
Three revenue surfaces. Each one buys down a specific class of regulatory or scientific friction.
$2,500/month
For preclinical discovery teams and academic labs.
$25,000/application
[LEGAL REVIEW] markers flag every ambiguityFor new Schedule I applicants. Saves roughly $15K and four weeks versus counsel-only drafting.
$50,000/engagement
For research facilities scaling for clinical supply.
Tier 2 (Q3 2026): CriOS Nova Psy API, $5,000 per seat per month. Tier 3 (2027): IND-support and DEA-registered compound characterization.
Founder and CEO, Crowe Logic, Inc. Chief Mycologist.
Twenty-plus years of applied mycology. Commercial operator, published author, and principal architect of the Crowe Logic AI platform now powering Crowe Psychedelics.
synapse-lang and
synapse-qubit-flow, scientific-computing languages
for quantum chemistry and drug-discovery workflows.
"I build the operator's tools. The platform in front of you is what happens when twenty years of mycology meet twenty years of systems engineering."
No signup. Real artifacts generated by this platform.
SMILES proposals, crystal-structure-guided rationale (PDB 6WHA and 6WGT), predicted Ki with interpolation basis, ADMET concerns, freedom-to-operate commentary. Grounded in PMIDs 27816818, 32699011, and 28129538.
Agent reportResearcher or analytical lab registration choice,
21 CFR 1301 sections, realistic 8 to 16 week
timeline, top three rejection risks with mitigations, IND
scope, state-level Arizona considerations.
Ten CFR citations, six [LEGAL REVIEW] markers.
Cover letter, research protocol summary, security plan (21 CFR 1301.71 through 76), three SOPs, facility diagram template, and DEA Form 225 field map. Every file watermarked DRAFT, Legal review required. Generated from a single YAML intake.
Thirty-minute screen-share of the CLI running on your compound of interest. Leave with a pre-populated reg-pack intake YAML and a decision on fit.